2016 Pipeline of Herpes Zoster (Shingles) Market Covering 11 Companies
PUNE, India, May 12, 2016 /PRNewswire-iReach/ -- Herpes Zoster (Shingles) Pipeline Market Companies Involved in Therapeutics Development are Astellas Pharma Inc., Beijing Minhai Biotechnology Co., Ltd, ContraVir Pharmaceuticals, Inc., Epiphany Biosciences, Inc., Foamix Pharmaceuticals Ltd., GeneOne Life Science, Inc., GlaxoSmithKline Plc, Merck & Co., Inc., NAL Pharmaceuticals Ltd., ReceptoPharm, Inc., TSRL, Inc.
Photo - http://photos.prnewswire.com/prnh/20160512/366865
The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects.
Inquire more about this research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=542563
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
- The report reviews pipeline therapeutics for Herpes Zoster (Shingles) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Herpes Zoster (Shingles) therapeutics and enlists all their major and minor projects
- The report assesses Herpes Zoster (Shingles) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles)
Complete research report of 68 pages with TOC is avaialble at http://www.rnrmarketresearch.com/herpes-zoster-shingles-pipeline-review-h1-2016-market-report.html
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Media Contact: Ritesh Tiwari, RnR Market Research, + 1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research